ESRP1 and small cell lung carcinoma: These results were consistent with previous functional experimental results, and proved that ESRP1 inhibits the activation of TGF-β/Smad signaling pathway by reducing the content of CARM1FL and thereby enhancing chemosensitivity of SCLC.